AR079836A1 - Formulaciones estabilizadas que contienen anticuerpos anti-receptor de interleuquina-6 (il-6r) - Google Patents
Formulaciones estabilizadas que contienen anticuerpos anti-receptor de interleuquina-6 (il-6r)Info
- Publication number
- AR079836A1 AR079836A1 ARP110100021A ARP110100021A AR079836A1 AR 079836 A1 AR079836 A1 AR 079836A1 AR P110100021 A ARP110100021 A AR P110100021A AR P110100021 A ARP110100021 A AR P110100021A AR 079836 A1 AR079836 A1 AR 079836A1
- Authority
- AR
- Argentina
- Prior art keywords
- pharmaceutical formulation
- approximately
- polysorbate
- antibody
- concentration
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61J—CONTAINERS SPECIALLY ADAPTED FOR MEDICAL OR PHARMACEUTICAL PURPOSES; DEVICES OR METHODS SPECIALLY ADAPTED FOR BRINGING PHARMACEUTICAL PRODUCTS INTO PARTICULAR PHYSICAL OR ADMINISTERING FORMS; DEVICES FOR ADMINISTERING FOOD OR MEDICINES ORALLY; BABY COMFORTERS; DEVICES FOR RECEIVING SPITTLE
- A61J1/00—Containers specially adapted for medical or pharmaceutical purposes
- A61J1/05—Containers specially adapted for medical or pharmaceutical purposes for collecting, storing or administering blood, plasma or medical fluids ; Infusion or perfusion containers
- A61J1/06—Ampoules or carpules
- A61J1/065—Rigid ampoules, e.g. glass ampoules
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/485—Morphinan derivatives, e.g. morphine, codeine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
- A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
- C07K16/244—Interleukins [IL]
- C07K16/248—IL-6
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/515—Complete light chain, i.e. VL + CL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Dermatology (AREA)
- Emergency Medicine (AREA)
- Endocrinology (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Hematology (AREA)
- Rheumatology (AREA)
- Physical Education & Sports Medicine (AREA)
- Transplantation (AREA)
- Pain & Pain Management (AREA)
- Biomedical Technology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
La presente proporciona formulaciones farmacéuticas que comprenden un anticuerpo humano que se une de modo específico al receptor de interleuquina-6 humana (hIL-6R). Las formulaciones pueden contener, además de un anticuerpo anti-hIL-6R, al menos un aminoácido, al menos un azucar y/o al menos un tensioactivo no ionico. Las formulaciones farmacéuticas de la presente solicitud muestran un grado sustancial de estabilidad del anticuerpo después de una conservacion durante varios meses. Reivindicacion 2: La formulacion farmacéutica de la reivindicacion 1, en la que el carbohidrato es un azucar seleccionado del grupo que consiste en sacarosa, glucosa, manitol, lactosa y trehalosa. Reivindicacion 7: La formulacion farmacéutica de una cualquiera de las reivindicaciones 1-6, en la que la histidina se encuentra a una concentracion de aproximadamente 5 a 50 mM. Reivindicacion 8: La formulacion farmacéutica de una cualquiera de las reivindicaciones 1-7, en la que el carbohidrato se encuentra a una concentracion de aproximadamente 1% al 20%. Reivindicacion 10: La formulacion farmacéutica de la reivindicacion 9, en la que dicho tensioactivo no ionico se selecciona del grupo que consiste en polisorbato 20, polisorbato 80 y monooleato de polioxietilensorbitán. Reivindicacion 12: La formulacion farmacéutica de una cualquiera de las reivindicaciones 9-11, en la que dicho tensioactivo no ionico se encuentra a una concentracion de aproximadamente 0,01% al 1%. Reivindicacion 13: La formulacion farmacéutica de una cualquiera de las reivindicaciones 9-12, que comprende: (i) de aproximadamente 25 a 200 mg/ml de dicho anticuerpo humano que se une de modo específico a hIL-6R; (ii) histidina de aproximadamente 10 a 25 mM; (iii) sacarosa de aproximadamente 5% al 10%; y (iv) polisorbato 20 de aproximadamente 0,1% al 0,2%. Reivindicacion 15: La formulacion farmacéutica de una cualquiera de las reivindicaciones 9-14, que comprende además arginina. Reivindicacion 16: La formulacion farmacéutica de la reivindicacion 15, en la que la arginina se encuentra a una concentracion de aproximadamente 5 a 100 mM. Reivindicacion 19: La formulacion farmacéutica de la reivindicacion 15, que comprende: (i) aproximadamente 175 mg/ml de dicho anticuerpo humano que se une de modo específico a hIL-6R; (ii) histidina aproximadamente 25 mM; (iii) sacarosa aproximadamente al 5%; (iv) polisorbato 20 aproximadamente al 0,2%; y (v) arginina aproximadamente 50 mM. Reivindicacion 23: La formulacion farmacéutica de la reivindicacion 19 o de la reivindicacion 20, en la que al menos 96% de la forma nativa de dicho anticuerpo se recupera después de nueve meses de conservacion a 5°C, segun se determina mediante una cromatografía líquida de alta resolucion de exclusion molecular (SE-HPLC).
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US29322710P | 2010-01-08 | 2010-01-08 |
Publications (1)
Publication Number | Publication Date |
---|---|
AR079836A1 true AR079836A1 (es) | 2012-02-22 |
Family
ID=44258720
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ARP110100021A AR079836A1 (es) | 2010-01-08 | 2011-01-05 | Formulaciones estabilizadas que contienen anticuerpos anti-receptor de interleuquina-6 (il-6r) |
Country Status (39)
Country | Link |
---|---|
US (4) | US9173880B2 (es) |
EP (4) | EP2521536B9 (es) |
JP (2) | JP5805660B2 (es) |
KR (1) | KR101787351B1 (es) |
CN (1) | CN102869346B (es) |
AR (1) | AR079836A1 (es) |
AU (1) | AU2011204311B2 (es) |
BR (1) | BR112012016618A2 (es) |
CA (1) | CA2790197C (es) |
CL (1) | CL2012001853A1 (es) |
CO (1) | CO6592078A2 (es) |
CR (1) | CR20120393A (es) |
CY (2) | CY1121420T1 (es) |
DK (3) | DK3756652T3 (es) |
DO (1) | DOP2012000193A (es) |
EC (1) | ECSP12012092A (es) |
ES (3) | ES2925665T3 (es) |
GT (1) | GT201200223A (es) |
HR (3) | HRP20221139T1 (es) |
HU (3) | HUE059811T2 (es) |
JO (1) | JO3417B1 (es) |
LT (3) | LT3409269T (es) |
MA (1) | MA33993B1 (es) |
MX (1) | MX2012007794A (es) |
MY (1) | MY156702A (es) |
NI (1) | NI201200119A (es) |
NZ (1) | NZ601114A (es) |
PE (2) | PE20170948A1 (es) |
PL (3) | PL2521536T3 (es) |
PT (3) | PT2521536T (es) |
RS (3) | RS57903B1 (es) |
RU (1) | RU2554779C2 (es) |
SG (1) | SG182283A1 (es) |
SI (3) | SI3756652T1 (es) |
TW (2) | TWI587870B (es) |
UA (1) | UA107211C2 (es) |
UY (1) | UY33169A (es) |
WO (1) | WO2011085158A2 (es) |
ZA (1) | ZA201205035B (es) |
Families Citing this family (82)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20130064834A1 (en) | 2008-12-15 | 2013-03-14 | Regeneron Pharmaceuticals, Inc. | Methods for treating hypercholesterolemia using antibodies to pcsk9 |
JO3672B1 (ar) | 2008-12-15 | 2020-08-27 | Regeneron Pharma | أجسام مضادة بشرية عالية التفاعل الكيماوي بالنسبة لإنزيم سبتيليسين كنفرتيز بروبروتين / كيكسين نوع 9 (pcsk9). |
JO3417B1 (ar) * | 2010-01-08 | 2019-10-20 | Regeneron Pharma | الصيغ المستقرة التي تحتوي على الأجسام المضادة لمضاد مستقبل( interleukin-6 (il-6r |
AR083035A1 (es) | 2010-09-17 | 2013-01-30 | Baxter Int | ESTABILIZACION DE INMUNOGLOBULINAS MEDIANTE UNA FORMULACION ACUOSA CON HISTIDINA A pH ACIDO DEBIL A NEUTRO, COMPOSICION ACUOSA DE INMUNOGLOBULINA |
EA034617B1 (ru) | 2010-10-06 | 2020-02-27 | Ридженерон Фармасьютикалз, Инк. | Дозированная форма жидкой фармацевтической композиции, содержащей антитела к рецептору интерлейкина-4 (il-4r) |
BR112013018740A2 (pt) | 2011-01-28 | 2019-01-08 | Sanofi Sa | anticorpos humanos para pcsk9 para uso em métodos de tratamento de grupos específicos de indivíduos |
AR087305A1 (es) | 2011-07-28 | 2014-03-12 | Regeneron Pharma | Formulaciones estabilizadas que contienen anticuerpos anti-pcsk9, metodo de preparacion y kit |
CN103930444B (zh) | 2011-09-16 | 2020-08-04 | 瑞泽恩制药公司 | 用前蛋白转化酶枯草溶菌素-9(PCSK9)抑制剂降低脂蛋白(a)水平的方法 |
TWI589299B (zh) * | 2011-10-11 | 2017-07-01 | 再生元醫藥公司 | 用於治療類風濕性關節炎之組成物及其使用方法 |
SG10201914052TA (en) * | 2011-10-11 | 2020-03-30 | Sanofi Biotechnology | Compositions for the treatment of rheumatoid arthritis and methods of using same |
US9943594B2 (en) | 2011-10-11 | 2018-04-17 | Sanofi Biotechnology | Methods for the treatment of rheumatoid arthritis |
JO3370B1 (ar) * | 2011-11-10 | 2019-03-13 | Regeneron Pharma | طريقة لتثبيط نمو الورم عن طريق تثبيط مستقبل انترلوكين 6 |
IL277958B2 (en) | 2011-11-18 | 2023-11-01 | Regeneron Pharma | Micro-particles of polymeric proteins |
EA033387B1 (ru) * | 2012-01-23 | 2019-10-31 | Regeneron Pharma | СТАБИЛИЗИРОВАННЫЕ СОСТАВЫ, СОДЕРЖАЩИЕ АНТИТЕЛА ПРОТИВ Ang-2 |
US9592289B2 (en) | 2012-03-26 | 2017-03-14 | Sanofi | Stable IgG4 based binding agent formulations |
PT2830658T (pt) * | 2012-03-26 | 2018-12-28 | Sanofi Sa | Formulações de agente de ligação igg4 estável |
EP2911693A4 (en) * | 2012-10-25 | 2016-04-27 | Medimmune Llc | STABLE, LOW-VISIC ANTIBODY FORMULATION |
CN104903349B (zh) | 2012-11-08 | 2018-10-19 | 十一生物治疗股份有限公司 | Il-6拮抗剂及其应用 |
AR095196A1 (es) | 2013-03-15 | 2015-09-30 | Regeneron Pharma | Medio de cultivo celular libre de suero |
US10111953B2 (en) | 2013-05-30 | 2018-10-30 | Regeneron Pharmaceuticals, Inc. | Methods for reducing remnant cholesterol and other lipoprotein fractions by administering an inhibitor of proprotein convertase subtilisin kexin-9 (PCSK9) |
US10494442B2 (en) | 2013-06-07 | 2019-12-03 | Sanofi Biotechnology | Methods for inhibiting atherosclerosis by administering an inhibitor of PCSK9 |
EP3882273A1 (en) | 2013-11-12 | 2021-09-22 | Sanofi Biotechnology | Dosing regimens for use with pcsk9 inhibitors |
DE202014010499U1 (de) | 2013-12-17 | 2015-10-20 | Kymab Limited | Targeting von humaner PCSK9 zur Cholesterinbehandlung |
US9017678B1 (en) | 2014-07-15 | 2015-04-28 | Kymab Limited | Method of treating rheumatoid arthritis using antibody to IL6R |
WO2015116852A1 (en) | 2014-01-29 | 2015-08-06 | Regeneron Pharmaceuticals, Inc. | Methods for treating rheumatoid arthritis by administering an il-6r antibody |
CA2955294A1 (en) | 2014-07-16 | 2016-01-21 | Sanofi Biotechnology | Methods for treating patients with heterozygous familial hypercholesterolemia (hefh) |
US11142571B2 (en) | 2014-11-07 | 2021-10-12 | Sesen Bio, Inc. | IL-6 antibodies |
AR104847A1 (es) * | 2015-06-17 | 2017-08-16 | Lilly Co Eli | Formulación de anticuerpo anti-cgrp |
TW202330904A (zh) | 2015-08-04 | 2023-08-01 | 美商再生元醫藥公司 | 補充牛磺酸之細胞培養基及用法 |
KR20180034672A (ko) | 2015-08-18 | 2018-04-04 | 리제너론 파아마슈티컬스, 인크. | 지단백질 분리반출술을 경험하고 있는 고지혈증을 갖는 환자를 치료하기 위한 항-pcsk9 억제성 항체 |
CA3012350A1 (en) * | 2016-02-23 | 2017-08-31 | Sesen Bio, Inc. | Il-6 antagonist formulations and uses thereof |
EP3216461A1 (en) | 2016-03-07 | 2017-09-13 | Sanofi Biotechnology | Compositions and methods for treating rheumatoid arthritis |
TWI747885B (zh) * | 2016-03-07 | 2021-12-01 | 法商賽諾菲生物技術公司 | 用於治療類風濕性關節炎之組成物及方法 |
WO2018039499A1 (en) | 2016-08-24 | 2018-03-01 | Regeneron Pharmaceuticals, Inc. | Host cell protein modification |
CN109862880A (zh) * | 2016-09-27 | 2019-06-07 | 德国费森尤斯卡比有限公司 | 液体药物组合物 |
WO2018081754A1 (en) * | 2016-10-29 | 2018-05-03 | University Of Miami | Anti-zika virus antibodies |
US11249082B2 (en) | 2016-10-29 | 2022-02-15 | University Of Miami | Zika virus assay systems |
ES2882181T3 (es) | 2016-10-31 | 2021-12-01 | Fresenius Kabi Deutschland Gmbh | Composición farmacéutica líquida |
WO2018116198A1 (en) * | 2016-12-23 | 2018-06-28 | Serum Institute Of India Private Limited | Improved methods for enhancing antibody productivity in mammalian cell culture and minimizing aggregation during downstream, formulation processes and stable antibody formulations obtained thereof |
EP3576790A4 (en) | 2017-02-01 | 2020-12-23 | Yale University | TREATMENT OF DIURETIC RESISTANCE |
CA3067847A1 (en) | 2017-07-06 | 2019-01-10 | Regeneron Pharmaceuticals, Inc. | Cell culture process for making a glycoprotein |
US20220071901A1 (en) * | 2017-11-30 | 2022-03-10 | Bio-Thera Solutions, Ltd. | A liquid formulation of humanized antibody for treating il-6-mediated diseases |
CN115925882A (zh) | 2017-12-22 | 2023-04-07 | 瑞泽恩制药公司 | 用于表征药物产品杂质的系统和方法 |
CA3087699A1 (en) | 2018-01-05 | 2019-07-11 | Corvidia Therapeutics, Inc. | Methods for treating il-6 mediated inflammation without immunosuppression |
SG11202005235WA (en) | 2018-01-31 | 2020-07-29 | Regeneron Pharma | System and method for characterizing size and charge variant drug product impurities |
TW202311746A (zh) | 2018-02-02 | 2023-03-16 | 美商再生元醫藥公司 | 用於表徵蛋白質二聚合之系統及方法 |
CA3088906A1 (en) | 2018-02-28 | 2019-09-06 | Regeneron Pharmaceuticals, Inc. | Systems and methods for identifying viral contaminants |
EA202092203A1 (ru) | 2018-03-19 | 2020-12-07 | Ридженерон Фармасьютикалз, Инк. | Способы анализа и реагенты для микрочипового капиллярного электрофореза |
TW202016125A (zh) | 2018-05-10 | 2020-05-01 | 美商再生元醫藥公司 | 用於定量及調節蛋白質黏度之系統與方法 |
US11830582B2 (en) | 2018-06-14 | 2023-11-28 | University Of Miami | Methods of designing novel antibody mimetics for use in detecting antigens and as therapeutic agents |
KR20210052389A (ko) | 2018-08-27 | 2021-05-10 | 리제너론 파마슈티칼스 인코포레이티드 | 다운스트림 정제에서의 라만 분광법의 사용 |
BR112021003206A2 (pt) | 2018-08-29 | 2021-05-25 | Regeneron Pharmaceuticals, Inc. | métodos e composições para tratar indivíduos com artrite reumatoide |
WO2020047067A1 (en) | 2018-08-30 | 2020-03-05 | Regeneron Pharmaceuticals, Inc. | Methods for characterizing protein complexes |
US20210393783A1 (en) * | 2018-10-31 | 2021-12-23 | Richter Gedeon Nyrt | Aqueous pharmaceutical formulations |
EP4220173A3 (en) | 2019-01-16 | 2023-10-18 | Regeneron Pharmaceuticals, Inc. | Methods for characterizing disulfide bonds |
KR20210122810A (ko) | 2019-01-31 | 2021-10-12 | 사노피 바이오테크놀로지 | 청소년 특발성 관절염을 치료하기 위한 항 il-6 수용체 항체 |
CA3129901A1 (en) | 2019-02-18 | 2020-08-27 | Eli Lilly And Company | Therapeutic antibody formulation |
TW202106712A (zh) | 2019-04-24 | 2021-02-16 | 美商再生元醫藥公司 | 類風溼性關節炎之診斷及治療方法 |
SG11202110911RA (en) | 2019-05-13 | 2021-10-28 | Regeneron Pharma | Improved competitive ligand binding assays |
AU2020288561A1 (en) | 2019-06-04 | 2021-12-23 | Regeneron Pharmaceuticals, Inc. | Compositions and methods for treating pain in subjects with rheumatoid arthritis |
EP3986481A2 (en) | 2019-06-20 | 2022-04-27 | Takeda Pharmaceutical Company Limited | Method of treatment with viral-based gene therapy |
KR20220066393A (ko) | 2019-09-24 | 2022-05-24 | 리제너론 파아마슈티컬스, 인크. | 크로마토그래피의 사용 및 재생을 위한 시스템 및 방법 |
IL293112A (en) | 2019-11-25 | 2022-07-01 | Regeneron Pharma | Sustained release formulations using non-aqueous emulsions |
WO2021150558A1 (en) | 2020-01-21 | 2021-07-29 | Regeneron Pharmaceuticals, Inc. | Deglycosylation methods for electrophoresis of glycosylated proteins |
WO2021163549A1 (en) | 2020-02-14 | 2021-08-19 | Sanofi Biotechnology | Compositions and methods for treating viral infections |
BR112022024020A2 (pt) | 2020-05-26 | 2023-04-04 | Feist Eugen | Composições compreendendo um anticorpo contra receptor de interleucina-6 para tratamento de artrite reumatoide e métodos de uso das mesmas |
CA3180041A1 (en) | 2020-05-29 | 2021-12-02 | Sanofi Biotechnology | Compositions and methods for treating non-inflammatory pain in subjects with rheumatoid arthritis |
CN115812080A (zh) * | 2020-07-08 | 2023-03-17 | 瑞泽恩制药公司 | 含有抗ctla-4抗体的稳定调配物 |
BR112023003273A2 (pt) | 2020-08-31 | 2023-05-02 | Regeneron Pharma | Estratégias de alimentação de asparagina para melhorar desempenho da cultura celular e mitigar variantes da sequência de asparagina |
KR20230113280A (ko) | 2020-11-25 | 2023-07-28 | 리제너론 파마슈티칼스 인코포레이티드 | 비수성 멤브레인 유화법을 사용한 지속 방출 제형 |
WO2022133135A1 (en) | 2020-12-17 | 2022-06-23 | Regeneron Pharmaceuticals, Inc. | Fabrication of protein-encapsulating microgels |
KR20230134117A (ko) | 2021-01-20 | 2023-09-20 | 리제너론 파마슈티칼스 인코포레이티드 | 세포 배양물에서 단백질 역가를 개선시키는 방법 |
WO2022187323A1 (en) | 2021-03-03 | 2022-09-09 | Regeneron Pharmaceuticals, Inc. | Systems and methods for quantifying and modifying protein viscosity |
CA3211302A1 (en) | 2021-03-26 | 2022-09-29 | Ross Kenyon | Methods and systems for developing mixing protocols |
KR20240015646A (ko) | 2021-06-01 | 2024-02-05 | 리제너론 파마슈티칼스 인코포레이티드 | 마이크로칩 모세관 전기영동 분석 및 시약 |
WO2023020563A1 (en) * | 2021-08-18 | 2023-02-23 | Bio-Thera Solutions, Ltd. | Liquid formulations comprising high concentrations humanized antibodies for treating il-6 related diseases |
AR127006A1 (es) | 2021-09-08 | 2023-12-06 | Regeneron Pharma | UN MÉTODO BASADO EN ESPECTROMETRÍA DE MASAS Y DE ALTO RENDIMIENTO PARA CUANTIFICAR ANTICUERPOS Y OTRAS PROTEÍNAS QUE CONTIENEN Fc |
KR20240058201A (ko) | 2021-09-20 | 2024-05-03 | 리제너론 파마슈티칼스 인코포레이티드 | 항체 이질성을 제어하는 방법 |
AU2022359898A1 (en) | 2021-10-07 | 2024-03-21 | Regeneron Pharmaceuticals, Inc. | Ph meter calibration and correction |
TW202323817A (zh) | 2021-10-07 | 2023-06-16 | 美商再生元醫藥公司 | Ph建模及控制之系統及方法 |
CA3236367A1 (en) | 2021-10-26 | 2023-05-04 | Michelle Lafond | Systems and methods for generating laboratory water and distributing laboratory water at different temperatures |
TW202346856A (zh) | 2022-03-18 | 2023-12-01 | 美商里珍納龍藥品有限公司 | 分析多肽變體的方法及系統 |
Family Cites Families (90)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US1007208A (en) | 1911-07-21 | 1911-10-31 | Axel W Johnson | Window. |
JPH0747045B2 (ja) | 1986-10-15 | 1995-05-24 | 株式会社大協精工 | 積層した注射器用滑栓 |
US5171840A (en) | 1988-01-22 | 1992-12-15 | Tadamitsu Kishimoto | Receptor protein for human B cell stimulatory factor-2 |
US5670373A (en) | 1988-01-22 | 1997-09-23 | Kishimoto; Tadamitsu | Antibody to human interleukin-6 receptor |
US5216128A (en) | 1989-06-01 | 1993-06-01 | Yeda Research And Development Co., Ltd. | IFN-β2/IL-6 receptor its preparation and pharmaceutical compositions containing it |
DE69029015T2 (de) | 1989-07-20 | 1998-01-22 | Tadamitsu Kishimoto | Antikörper gegen menschlichen Interleukin-6-Rezeptor |
US5605690A (en) | 1989-09-05 | 1997-02-25 | Immunex Corporation | Methods of lowering active TNF-α levels in mammals using tumor necrosis factor receptor |
US5859205A (en) | 1989-12-21 | 1999-01-12 | Celltech Limited | Humanised antibodies |
US5016784A (en) * | 1990-02-15 | 1991-05-21 | Dexus Research Inc. | Applicator for highly reactive materials |
DK1097945T3 (da) | 1991-03-18 | 2007-11-05 | Univ New York | Monoklonale og kimære antistoffer, der er specifikke for human tumornekrosefaktor |
RU2139351C1 (ru) | 1991-04-25 | 1999-10-10 | Чугаи Сейяку Кабусики Кайся | Н- и l-цепи моноклонального антитела рм1 (монат) к рецептору il-6r человека и их v-области, модифицированная монат, его н- и l-цепи и их v-области, cdr- последовательности, днк-последовательности |
JP3100727B2 (ja) | 1992-01-23 | 2000-10-23 | 株式会社大協精工 | 変性ポリシロキサン組成物及び該組成物を被覆した衛生ゴム製品 |
FR2694767B1 (fr) | 1992-08-13 | 1994-10-21 | Innotherapie Lab Sa | Anticorps monoclonaux anti-IL6R, et leurs applications. |
KR100232688B1 (ko) | 1992-09-15 | 1999-12-01 | 스코트 쥐. 홀퀴스트 | 종양 괴사 인자 길항제를 함유하는 tnf-의존성 염증 치료용 제약 조성물 |
CA2147466A1 (en) | 1992-10-20 | 1994-04-28 | Just P. J. Brakenhoff | Interleukin-6 receptor antagonists |
US5888511A (en) | 1993-02-26 | 1999-03-30 | Advanced Biotherapy Concepts, Inc. | Treatment of autoimmune diseases, including AIDS |
US5888510A (en) | 1993-07-21 | 1999-03-30 | Chugai Seiyaku Kabushiki Kaisha | Chronic rheumatoid arthritis therapy containing IL-6 antagonist as effective component |
WO1995009873A1 (en) | 1993-10-06 | 1995-04-13 | Board Of Regents, The University Of Texas System | A monoclonal anti-human il-6 receptor antibody |
DK0783893T3 (da) | 1994-10-07 | 2012-05-29 | Chugai Pharmaceutical Co Ltd | Inhibering af unormal vækst af synovial-celler under anvendelse af il-6-antagonist som aktiv bestanddel |
EP0791359A4 (en) | 1994-10-21 | 2002-09-11 | Chugai Pharmaceutical Co Ltd | MEDICINE AGAINST IL-6 PRODUCTION IN DISEASES |
JP4079461B2 (ja) | 1994-12-29 | 2008-04-23 | 中外製薬株式会社 | Il−6アンタゴニストを含んでなる抗腫瘍剤の作用増強剤 |
ES2264135T3 (es) | 1995-02-13 | 2006-12-16 | Chugai Seiyaku Kabushiki Kaisha | Inhibidor de la descomposicion de proteinas musculares que contienen anticuerpos frente al receptor de il-6. |
JP3172057B2 (ja) | 1995-04-05 | 2001-06-04 | 株式会社大協精工 | ラミネートゴム栓 |
ZA971600B (en) | 1996-02-26 | 1997-09-22 | Merck & Co Inc | Treatment of macular edema. |
ATE326238T1 (de) | 1996-06-27 | 2006-06-15 | Chugai Pharmaceutical Co Ltd | Mittel gegen myelome, welches zusammen mit antitumorwirkstoffen auf der basis von stickstoff-senfgasen verwendet werden kann |
US5795695A (en) | 1996-09-30 | 1998-08-18 | Xerox Corporation | Recording and backing sheets containing linear and cross-linked polyester resins |
US7312196B2 (en) | 1997-01-08 | 2007-12-25 | Amylin Pharmaceuticals, Inc. | Formulations for amylin agonist peptides |
DK1004315T3 (da) | 1997-08-15 | 2008-07-21 | Chugai Pharmaceutical Co Ltd | Forebyggende midler og/eller lægemidler indeholdende anti-IL6-receptorneutraliserende antistoffer til reduktion af urinproteinudskillelsen ved systemisk lupus erythematosus |
US20020187150A1 (en) | 1997-08-15 | 2002-12-12 | Chugai Seiyaku Kabushiki Kaisha | Preventive and/or therapeutic agent for systemic lupus erythematosus comprising anti-IL-6 receptor antibody as an active ingredient |
PL201461B1 (pl) | 1998-03-17 | 2009-04-30 | Chugai Pharmaceutical Co Ltd | Czynnik zapobiegający lub terapeutyczny do leczenia zapalenia jelita, zawierający antagonistę IL-6 jako składnik aktywny |
ATE350060T1 (de) | 1998-08-24 | 2007-01-15 | Chugai Pharmaceutical Co Ltd | Mittel zur vorbeugung oder behandlung von pankreatitis die anti-il-6 receptor antikörper als aktive komponente enthalten |
JP3512349B2 (ja) | 1999-01-29 | 2004-03-29 | 株式会社大協精工 | 柱状ゴム要素の成形型 |
AU7824900A (en) | 1999-10-07 | 2001-04-23 | Eli Lilly And Company | Compounds and methods for inhibiting mrp1 |
US6629949B1 (en) | 2000-05-08 | 2003-10-07 | Sterling Medivations, Inc. | Micro infusion drug delivery device |
US6659982B2 (en) | 2000-05-08 | 2003-12-09 | Sterling Medivations, Inc. | Micro infusion drug delivery device |
ES2644275T3 (es) * | 2000-08-11 | 2017-11-28 | Chugai Seiyaku Kabushiki Kaisha | Preparaciones estabilizadas que contienen anticuerpos |
US7148197B2 (en) | 2000-08-24 | 2006-12-12 | The Regents Of The University Of California | Orally administered small peptides synergize statin activity |
WO2002033073A1 (fr) | 2000-10-20 | 2002-04-25 | Chugai Seiyaku Kabushiki Kaisha | Anticorps agoniste degrade |
EP1334731B1 (en) | 2000-10-25 | 2008-02-27 | Chugai Seiyaku Kabushiki Kaisha | Preventives or remedies for psoriasis containing as the active ingredient il-6 antagonist |
JP4889187B2 (ja) | 2000-10-27 | 2012-03-07 | 中外製薬株式会社 | Il−6アンタゴニストを有効成分として含有する血中mmp−3濃度低下剤 |
JP2002209975A (ja) | 2001-01-19 | 2002-07-30 | Daikyo Seiko Ltd | 医薬バイアル用ラミネートゴム栓 |
UA80091C2 (en) | 2001-04-02 | 2007-08-27 | Chugai Pharmaceutical Co Ltd | Remedies for infant chronic arthritis-relating diseases and still's disease which contain an interleukin-6 (il-6) antagonist |
CA2868614A1 (en) | 2001-06-08 | 2002-12-08 | Abbott Laboratories (Bermuda) Ltd. | Methods of administering anti-tnf.alpha. antibodies |
WO2003009817A2 (en) | 2001-07-25 | 2003-02-06 | Protein Design Labs, Inc. | Stable lyophilized pharmaceutical formulation of igg antibodies |
KR20100120246A (ko) * | 2001-11-14 | 2010-11-12 | 센토코 오르토 바이오테크 인코포레이티드 | 항 il-6 항체, 조성물, 방법 및 용도 |
EP3192528A1 (en) | 2002-02-14 | 2017-07-19 | Chugai Seiyaku Kabushiki Kaisha | Formulation of anti-il6r antibody-containing solutions comprising a sugar as a stabilizer |
US20060078532A1 (en) | 2004-10-12 | 2006-04-13 | Omoigui Osemwota S | Method of prevention and treatment of Atherosclerosis, Peripheral vascular disease, Coronary artery disease, aging and age-related disorders including osteoporosis, arthritis, type 2 diabetes, dementia and Alzheimer's disease |
US20060078533A1 (en) | 2004-10-12 | 2006-04-13 | Omoigui Osemwota S | Method of prevention and treatment of aging and age-related disorders including atherosclerosis, peripheral vascular disease, coronary artery disease, osteoporosis, arthritis, type 2 diabetes, dementia, alzheimer's disease and cancer |
US20060275294A1 (en) | 2002-08-22 | 2006-12-07 | Omoigui Osemwota S | Method of prevention and treatment of aging, age-related disorders and/or age-related manifestations including atherosclerosis, peripheral vascular disease, coronary artery disease, osteoporosis, arthritis, type 2 diabetes, dementia, alzheimers disease and cancer |
US20060078531A1 (en) | 2004-10-12 | 2006-04-13 | Osemwota Sota | Method of prevention and treatment of atherosclerosis, peripheral vascular disease, coronary artery disease, and age-related disorders including osteoporosis, arthritis, type 2 diabetes, dementia and Alzheimer's disease |
US7534427B2 (en) | 2002-12-31 | 2009-05-19 | Immunomedics, Inc. | Immunotherapy of B cell malignancies and autoimmune diseases using unconjugated antibodies and conjugated antibodies and antibody combinations and fusion proteins |
LT2335725T (lt) * | 2003-04-04 | 2017-01-25 | Genentech, Inc. | Didelės koncentracijos antikūno ir baltymo kompozicijos |
US20040202658A1 (en) | 2003-04-09 | 2004-10-14 | Genentech, Inc. | Therapy of autoimmune disease in a patient with an inadequate response to TNF-alpha inhibitor |
GB2401040A (en) | 2003-04-28 | 2004-11-03 | Chugai Pharmaceutical Co Ltd | Method for treating interleukin-6 related diseases |
EP1673396A1 (en) | 2003-09-22 | 2006-06-28 | BioVation GmbH & Co.KG. | Use of antibodies for reducing the biological effectiveness of il-6 |
DE10355251A1 (de) | 2003-11-26 | 2005-06-23 | Merck Patent Gmbh | Pharmazeutische Zubereitung enthaltend einen Antikörper gegen den EGF-Rezeptor |
US8617550B2 (en) | 2003-12-19 | 2013-12-31 | Chugai Seiyaku Kabushiki Kaisha | Treatment of vasculitis with IL-6 antagonist |
BRPI0506679A (pt) | 2004-02-11 | 2007-05-15 | Warner Lambert Co | métodos de tratar osteoartrite com antagonistas de il-6 |
AU2005247341B2 (en) | 2004-05-06 | 2008-05-08 | The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Methods and compositions for the treatment of uveitis |
EP1791563A4 (en) | 2004-07-26 | 2009-07-08 | Biogen Idec Inc | ANTI-CD154 ANTIBODIES |
US20070036788A1 (en) | 2004-09-22 | 2007-02-15 | Ahmed Sheriff | Use of a compound for reducing the biological effectiveness of il-6 |
EP1810980A1 (en) | 2004-10-28 | 2007-07-25 | Osaka University | Interleukin-6 inhibitors |
EP1828250A2 (en) | 2004-12-16 | 2007-09-05 | Genentech, Inc. | Methods for treating autoimmune disorders |
WO2007062040A1 (en) | 2005-11-22 | 2007-05-31 | Wyeth | Immunoglobulin fusion protein formulations |
HUE039353T2 (hu) | 2005-12-13 | 2018-12-28 | Lilly Co Eli | Anti-IL-17 ellenanyagok |
US20080131374A1 (en) | 2006-04-19 | 2008-06-05 | Medich John R | Uses and compositions for treatment of rheumatoid arthritis |
US8080248B2 (en) | 2006-06-02 | 2011-12-20 | Regeneron Pharmaceuticals, Inc. | Method of treating rheumatoid arthritis with an IL-6R antibody |
MY159787A (en) | 2006-06-02 | 2017-01-31 | Regeneron Pharma | High affinity antibodies to human il-6 receptor |
KR20090021298A (ko) | 2006-06-14 | 2009-03-02 | 임클론 시스템즈 인코포레이티드 | 항-egfr 항체의 동결건조 제제 |
CA2666599A1 (en) | 2006-08-18 | 2008-02-21 | Ablynx N.V. | Amino acid sequences directed against il-6r and polypeptides comprising the same for the treatment of diseases and disorders associated with il-6-mediated signalling |
EP2081960B1 (en) | 2006-10-27 | 2018-06-27 | Ablynx N.V. | Intranasal delivery of polypeptides and proteins |
US20100267934A1 (en) | 2007-05-31 | 2010-10-21 | Genmab A/S | Stable igg4 antibodies |
BRPI0817250A2 (pt) | 2007-09-26 | 2014-06-17 | Chugai Pharmaceutical Co Ltd | Anticorpo anti-receptor da il-6. |
PE20091174A1 (es) | 2007-12-27 | 2009-08-03 | Chugai Pharmaceutical Co Ltd | Formulacion liquida con contenido de alta concentracion de anticuerpo |
WO2009095489A2 (en) | 2008-02-01 | 2009-08-06 | Ablynx N.V. | Improved amino acid sequences directed against il-6r and polypeptides comprising the same for the treatment of diseases and disorders associated with il-6-mediated signalling |
WO2009109584A1 (en) | 2008-03-07 | 2009-09-11 | Ferring International Center S. A. | ANTIBODY BINDING ONLY TO IL6-sIL6R COMPLEX |
EP3521311A1 (en) | 2008-04-11 | 2019-08-07 | Chugai Seiyaku Kabushiki Kaisha | Antigen-binding molecule capable of binding to two or more antigen molecules repeatedly |
TWI440469B (zh) | 2008-09-26 | 2014-06-11 | Chugai Pharmaceutical Co Ltd | Improved antibody molecules |
JP4885308B2 (ja) * | 2009-03-19 | 2012-02-29 | 中外製薬株式会社 | 改良された抗体分子を含有する製剤 |
JO3030B1 (ar) | 2009-06-26 | 2016-09-05 | Galapagos Nv | مركب جديد مفيد لمعالجة الامراض التنكسية والالتهابات |
JO3417B1 (ar) | 2010-01-08 | 2019-10-20 | Regeneron Pharma | الصيغ المستقرة التي تحتوي على الأجسام المضادة لمضاد مستقبل( interleukin-6 (il-6r |
MX337586B (es) | 2010-05-07 | 2016-03-11 | Xoma Us Llc | Anticuerpos anti-interleucina-1beta para usarse en el tratamiento de condiciones relacionadas con interleucina-1beta. |
TWI589299B (zh) | 2011-10-11 | 2017-07-01 | 再生元醫藥公司 | 用於治療類風濕性關節炎之組成物及其使用方法 |
US9943594B2 (en) | 2011-10-11 | 2018-04-17 | Sanofi Biotechnology | Methods for the treatment of rheumatoid arthritis |
US20150050277A1 (en) | 2013-03-15 | 2015-02-19 | Aerpio Therapeutics Inc. | Compositions and methods for treating ocular diseases |
AU2014352801B2 (en) | 2013-11-22 | 2020-05-28 | Regeneron Pharmaceuticals, Inc. | Compositions for the treatment of rheumatoid arthritis and methods of using same |
KR102555955B1 (ko) | 2014-03-27 | 2023-07-18 | 다케다 파머수티컬 컴패니 리미티드 | 당뇨병성 황반 부종의 치료를 위한 조성물 및 방법 |
US20170252434A1 (en) | 2014-09-16 | 2017-09-07 | Sanofi Biotechnology | Compositions for improving the health related quality of life of rheumatoid arthritis patients |
KR20180073680A (ko) | 2015-11-03 | 2018-07-02 | 사노피 바이오테크놀로지, 소시에떼 빠르 악씨옹 셍쁠리피에 | 포도막염 및 황반 부종의 치료를 위한 il6r 항체를 포함하는 조성물 및 이를 이용하는 방법 |
TWI747885B (zh) | 2016-03-07 | 2021-12-01 | 法商賽諾菲生物技術公司 | 用於治療類風濕性關節炎之組成物及方法 |
-
2010
- 2010-12-09 JO JOP/2010/0440A patent/JO3417B1/ar active
-
2011
- 2011-01-05 AR ARP110100021A patent/AR079836A1/es not_active Application Discontinuation
- 2011-01-07 PT PT11703294T patent/PT2521536T/pt unknown
- 2011-01-07 TW TW104126027A patent/TWI587870B/zh active
- 2011-01-07 CA CA2790197A patent/CA2790197C/en active Active
- 2011-01-07 LT LTEP18174400.4T patent/LT3409269T/lt unknown
- 2011-01-07 SI SI201132064T patent/SI3756652T1/sl unknown
- 2011-01-07 KR KR1020127020667A patent/KR101787351B1/ko active IP Right Grant
- 2011-01-07 PT PT181744004T patent/PT3409269T/pt unknown
- 2011-01-07 MA MA35130A patent/MA33993B1/fr unknown
- 2011-01-07 RU RU2012133970/15A patent/RU2554779C2/ru active
- 2011-01-07 DK DK20184418.0T patent/DK3756652T3/da active
- 2011-01-07 SI SI201131598T patent/SI2521536T1/sl unknown
- 2011-01-07 PE PE2017000859A patent/PE20170948A1/es unknown
- 2011-01-07 MX MX2012007794A patent/MX2012007794A/es active IP Right Grant
- 2011-01-07 UY UY0001033169A patent/UY33169A/es active IP Right Grant
- 2011-01-07 TW TW100100565A patent/TWI533884B/zh active
- 2011-01-07 RS RS20181286A patent/RS57903B1/sr unknown
- 2011-01-07 PT PT201844180T patent/PT3756652T/pt unknown
- 2011-01-07 PE PE2012000970A patent/PE20121687A1/es active IP Right Grant
- 2011-01-07 AU AU2011204311A patent/AU2011204311B2/en active Active
- 2011-01-07 HU HUE20184418A patent/HUE059811T2/hu unknown
- 2011-01-07 SI SI201131915T patent/SI3409269T1/sl unknown
- 2011-01-07 LT LTEP11703294.6T patent/LT2521536T/lt unknown
- 2011-01-07 DK DK11703294.6T patent/DK2521536T3/en active
- 2011-01-07 HU HUE11703294A patent/HUE040403T2/hu unknown
- 2011-01-07 EP EP11703294.6A patent/EP2521536B9/en active Active
- 2011-01-07 SG SG2012047767A patent/SG182283A1/en unknown
- 2011-01-07 MY MYPI2012002936A patent/MY156702A/en unknown
- 2011-01-07 ES ES20184418T patent/ES2925665T3/es active Active
- 2011-01-07 HU HUE18174400A patent/HUE051115T2/hu unknown
- 2011-01-07 RS RS20201334A patent/RS61045B1/sr unknown
- 2011-01-07 ES ES11703294.6T patent/ES2688070T3/es active Active
- 2011-01-07 DK DK18174400.4T patent/DK3409269T3/da active
- 2011-01-07 WO PCT/US2011/020457 patent/WO2011085158A2/en active Application Filing
- 2011-01-07 ES ES18174400T patent/ES2818992T3/es active Active
- 2011-01-07 PL PL11703294T patent/PL2521536T3/pl unknown
- 2011-01-07 PL PL20184418.0T patent/PL3756652T3/pl unknown
- 2011-01-07 JP JP2012548134A patent/JP5805660B2/ja active Active
- 2011-01-07 EP EP22172959.3A patent/EP4098247A1/en active Pending
- 2011-01-07 PL PL18174400T patent/PL3409269T3/pl unknown
- 2011-01-07 NZ NZ601114A patent/NZ601114A/en unknown
- 2011-01-07 LT LTEP20184418.0T patent/LT3756652T/lt unknown
- 2011-01-07 RS RS20220856A patent/RS63567B1/sr unknown
- 2011-01-07 EP EP18174400.4A patent/EP3409269B1/en active Active
- 2011-01-07 CN CN201180012860.1A patent/CN102869346B/zh active Active
- 2011-01-07 US US12/986,223 patent/US9173880B2/en active Active
- 2011-01-07 BR BR112012016618-2A patent/BR112012016618A2/pt not_active Application Discontinuation
- 2011-01-07 HR HRP20221139TT patent/HRP20221139T1/hr unknown
- 2011-01-07 EP EP20184418.0A patent/EP3756652B1/en active Active
- 2011-07-01 UA UAA201209619A patent/UA107211C2/ru unknown
-
2012
- 2012-07-05 ZA ZA2012/05035A patent/ZA201205035B/en unknown
- 2012-07-05 DO DO2012000193A patent/DOP2012000193A/es unknown
- 2012-07-06 GT GT201200223A patent/GT201200223A/es unknown
- 2012-07-06 CL CL2012001853A patent/CL2012001853A1/es unknown
- 2012-07-06 NI NI201200119A patent/NI201200119A/es unknown
- 2012-07-23 CR CR20120393A patent/CR20120393A/es unknown
- 2012-08-07 EC ECSP12012092 patent/ECSP12012092A/es unknown
- 2012-08-08 CO CO12132768A patent/CO6592078A2/es unknown
-
2015
- 2015-09-01 JP JP2015171642A patent/JP6053886B2/ja active Active
- 2015-09-22 US US14/861,565 patent/US10072086B2/en active Active
-
2018
- 2018-08-09 US US16/100,020 patent/US11098127B2/en active Active
- 2018-10-30 CY CY20181101111T patent/CY1121420T1/el unknown
- 2018-10-31 HR HRP20181821TT patent/HRP20181821T1/hr unknown
-
2020
- 2020-09-08 HR HRP20201428TT patent/HRP20201428T1/hr unknown
- 2020-11-11 CY CY20201101064T patent/CY1123909T1/el unknown
-
2021
- 2021-04-08 US US17/225,887 patent/US20210230283A1/en active Pending
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AR079836A1 (es) | Formulaciones estabilizadas que contienen anticuerpos anti-receptor de interleuquina-6 (il-6r) | |
AR089787A1 (es) | Formulaciones estabilizadas que contienen anticuerpos anti-ang2 | |
HRP20120903T1 (hr) | Tekuä†a formulacija koja sadrži visoku koncentraciju protutijela | |
PH12017500844A1 (en) | Stable protein solution formulation containing high concentration of an anti-vegf antibody | |
JP2013543505A5 (es) | ||
RU2015119547A (ru) | Стабильный низковязкий состав с антителом | |
AU2005249360B2 (en) | Anti-IL-9 antibody formulations and uses thereof | |
RU2017107847A (ru) | Стабильный состав на основе антитела к il-4r-альфа | |
AU2016204371A1 (en) | Lyophilised and aqueous anti-CD40 antibody formulations | |
AR082171A1 (es) | Formulaciones estabilizadas que contienen anticuerpos anti-ngf | |
NZ609557A (en) | Stabilized formulations containing anti-interleukin-4 receptor (il-4r) antibodies | |
RU2014140137A (ru) | Лекарственный препарат антитела к бета-амилоиду | |
EA202193240A1 (ru) | Стабилизированные составы, содержащие анти-angptl3 антитела | |
JPWO2008029908A1 (ja) | 抗体を含有する安定な凍結乾燥医薬製剤 | |
AR083338A1 (es) | Formulaciones estabilizadas que contienen anticuerpos anti-receptor de interleucina-4 (il-4r) | |
CL2021001587A1 (es) | Formulación de solución de proteínas que contiene una alta concentración de un anticuerpo anti-vegf | |
US20200299371A1 (en) | Pharmaceutical composition comprising pegylated fab' fragment of anti-human ngf antibody | |
TH128159A (th) | สูตรผสมที่มีเสถียรภาพที่มีแอนติบอดีแอนติ-อินเตอร์ลูคิน-6-รีเซพเตอร์ (il-6r) | |
RU2019136641A (ru) | Устойчивая жидкая фармацевтическая композиция | |
TH128159B (th) | สูตรผสมที่มีเสถียรภาพที่มีแอนติบอดีแอนติ-อินเตอร์ลูคิน-6-รีเซพเตอร์ (il-6r) | |
TH59466B (th) | สารผสมตามสูตรของเหลวชนิดมีแอนติบอดีในความเข้มข้นที่สูง | |
TH175929A (th) | สูตรตำรับของแอนติบอดี้ (Antibody Formulation) |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FC | Refusal |